Study of SHR-A1904 for advanced neuroendocrine carcinoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called SHR-A1904 for people with advanced neuroendocrine carcinoma that has grown after standard chemotherapy. The drug is given alone and may help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced neuroendocrine carcinoma confirmed by biopsy.
- Your cancer has progressed after at least one line of platinum-based chemotherapy.
- You have a tumor sample available (from within the last 2 years or a fresh biopsy).
- You have at least one measurable tumor that has not been treated with radiation.
- You are able to care for yourself (ECOG performance status 0 or 1).
- Your blood counts, liver, kidney, and heart function are within required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called SHR-A1904 in people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug, SHR-A2102, against the usual treatments for people with advanced bladder cancer that has spread. It is for those whose cancer has worsened after platinum chemotherapy and immunotherapy.
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
This trial tests a new drug called SHR-3821 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called SHR-A1904 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has already been treated once. It is for those whose tumors are positive for a protein called CLDN18.2.
Hear when a new Advanced Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.